Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shire Targets SHP465 ADHD Resubmission 10 Years After Initial Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire says it is on track to refile its long-shelved ADHD candidate SHP465 later this year after a Phase III trial in children and adolescents turned out positively.

Advertisement

Related Content

Shire Finally Gets Resuscitated Adult ADHD Drug Back On Track With FDA
Vyvanse’s Long Shadow: Launch To Decide Fate Of Two Other Shire Drugs
Shire Receives FDA “Approvable” Letter On Adult Adderall Product

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel